Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 89

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 89
---
 to retain key executives and to attract, retain and motivate qualified personnel.

Kadimastem’s future
success depends to a large extent on the continued services of members of its current management including, in particular, Professor Michel
Ravel, its VP Research and Development, and Dr. Kfir Molekandov, its Vice President of Research and Development, Dr. Ariel Revel, Director
of Medical Affairs, and Ronen Twito, its Chief Executive Officer. Any of Kadimastem’s employees and consultants may leave the company
at any time, subject to certain notice periods. The loss of the services of any of Kadimastem’s executive officers or any key employees
or consultants may adversely affect its ability to execute its business plan and harm its operating results. Kadimastem’s operational
success will substantially depend on the continued employment of senior executives, technical staff and other key personnel, especially
given the intense competition for qualified personnel. The loss of key personnel may have an adverse effect on Kadimastem’s operations
and financial performance.

Recruiting
and retaining qualified scientific and clinical personnel and, if Kadimastem progresses the development of its product pipeline toward
scaling up for commercialization, manufacturing and sales and marketing personnel, will also be critical to Kadimastem’s success.
The loss of the services of its executive officers or other key employees could impede the achievement of its development and commercialization
objectives and seriously harm its ability to successfully implement its business strategy. Furthermore, replacing executive officers and
key employees may be difficult and may take an extended period of time because of the limited number of individuals in its industry with
the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition
to hire from this limited pool is intense, and Kadimastem may be unable to hire, train, retain or motivate these key personnel on acceptable
terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. It also experience competition
for the hiring of scientific and clinical personnel from universities and research institutions. In addition, Kadimastem relies on consultants
and advisors, including scientific and clinical advisors, to assist Kadimastem in formulating its development and commercialization strategy.
Kadimastem’s consultants and advisors may be employed by employers other than Kadimastem and may have commitments under consulting
or advisory contracts with other entities that may limit their availability to Kadimastem. If Kadimastem